Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SER-287 + vancomycin
- Development stage
- Unknown
- Lead developer
- Seres Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SER-287 + vancomycin is a combination therapy consisting of oral SER-287, a spore-based microbiome therapeutic derived from Firmicutes bacteria, and oral vancomycin, an antibiotic. This regimen is being investigated for the treatment of mild-to-moderate ulcerative colitis (UC). Vancomycin is used as a short preconditioning course to reduce native gut microbiota diversity and open ecological niches in the gastrointestinal tract. This facilitates robust engraftment of the beneficial bacterial spores delivered by SER-287. The mechanism involves modulation of the gut microbiome composition—specifically increasing spore-forming Firmicutes associated with colonic homeostasis and reducing pro-inflammatory species such as Enterobacteriaceae—leading to changes in microbe-associated metabolites that may improve epithelial barrier function and immune signaling. Clinical studies have shown that this combination can induce clinical remission in UC patients; however, efficacy results have been mixed across different trial phases[1][2][5][6][7].
02
Targets
D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on SER-287 + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SER-287 + vancomycin.